AC Immune (ACIU)
NASDAQ:ACIU
Want to see ACIU full AI Analyst Report?
Top Page
AC Immune SA
(NASDAQ:ACIU)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.50
▼(-16.94% Downside)
Action:Reiterated
Date:04/08/26
The score is held back primarily by ongoing unprofitability and the 2025 shift back to significant cash burn alongside declining revenue and erosion of equity, despite the offsetting benefit of low leverage. Technically, the stock sits slightly above key moving averages but lacks positive momentum (negative MACD and sub-50 RSI). Valuation support is limited given the negative P/E and no dividend yield.
Positive Factors
Partner funding and milestone-rich collaborations
The amended collaboration with Eli Lilly delivers non-dilutive CHF10m upfront plus access to large development and commercial milestones. Such structured partner funding both validates AC Immune’s assets and materially reduces near-term financing pressure, supporting execution through clinical inflection points.
Negative Factors
Persistent structural unprofitability
AC Immune has sustained large operating and net losses across reported years with deeply negative margins. Without evidence of durable operating leverage, the business remains dependent on external funding rather than internally generated profits, limiting self-sustaining growth over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Partner funding and milestone-rich collaborations
The amended collaboration with Eli Lilly delivers non-dilutive CHF10m upfront plus access to large development and commercial milestones. Such structured partner funding both validates AC Immune’s assets and materially reduces near-term financing pressure, supporting execution through clinical inflection points.
Read all positive factors
AC Immune SA (ACIU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$279.88M
Dividend YieldN/A
Average Volume (3M)258.06K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth-85.87%
EPS Growth-41.37%
CountryUS
Employees133
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding101,773,575
10 Day Avg. Volume236,309
30 Day Avg. Volume258,063
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)5.58
Price to Sales (P/S)70.23
P/FCF Ratio-3.74
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue57.23
Enterprise Value/Gross Profit57.23
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$10.00Price Target Upside232.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$30.86M
AC Immune SA Business Overview & Revenue Model
Company Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Mo...
How the Company Makes Money
AC Immune primarily makes money through a partnering/licensing model typical of clinical-stage biotech companies, supplemented by collaboration-related services/reimbursements and, to the extent applicable in a given period, milestone and royalty ...
AC Immune SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.57M | 27.31M | 14.80M | 3.94M | 0.00 |
| Gross Profit | 3.57M | -35.26M | -39.80M | 3.94M | 0.00 |
| EBITDA | -67.75M | -48.62M | -51.83M | -68.03M | -70.01M |
| Net Income | -70.45M | -50.92M | -54.23M | -70.75M | -73.00M |
Balance Sheet | |||||
| Total Assets | 154.43M | 230.91M | 182.81M | 185.94M | 261.44M |
| Cash, Cash Equivalents and Short-Term Investments | 91.52M | 165.49M | 103.05M | 122.59M | 198.22M |
| Total Debt | 4.55M | 5.43M | 3.50M | 2.80M | 2.91M |
| Total Liabilities | 109.49M | 118.64M | 22.17M | 16.95M | 29.46M |
| Stockholders Equity | 44.93M | 112.27M | 160.64M | 168.99M | 231.98M |
Cash Flow | |||||
| Free Cash Flow | -67.01M | 65.27M | -61.21M | -74.81M | -68.32M |
| Operating Cash Flow | -66.15M | 65.84M | -60.41M | -73.57M | -65.69M |
| Investing Cash Flow | 60.69M | -105.29M | 65.64M | 23.76M | -53.66M |
| Financing Cash Flow | -974.14K | -1.12M | 43.25M | -1.35M | 40.75M |
AC Immune SA Technical Analysis
Negative
3.01
Price Trends
2.93
Negative
3.04
Negative
2.96
Negative
Market Momentum
-0.03
Negative
42.13
Neutral
51.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Negative. The current price of 3.01 is above the 20-day moving average (MA) of 2.88, above the 50-day MA of 2.93, and above the 200-day MA of 2.96, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.13 is Neutral, neither overbought nor oversold. The STOCH value of 51.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACIU.
AC Immune SA Risk Analysis
AC Immune SA disclosed 82 risk factors in its most recent earnings report. AC Immune SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AC Immune SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.38B | -5.32 | -85.61% | ― | ― | -68.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $813.33M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
49 Neutral | $279.88M | -3.09 | -123.98% | ― | -85.87% | -41.37% | |
46 Neutral | $335.82M | -3.11 | -677.38% | ― | 7.97% | 59.82% | |
46 Neutral | $250.71M | -3.95 | 85.78% | ― | 20.08% | 14.06% | |
42 Neutral | $238.70M | -1.91 | -295.17% | ― | -79.15% | 5.68% |
* Healthcare Sector Average
ACIU
AC Immune SA
2.66
0.95
55.56%
EDIT
Editas Medicine
3.46
1.74
101.16%
ALEC
Alector
2.16
0.83
62.41%
MLTX
MoonLake Immunotherapeutics
19.18
-19.83
-50.83%
FHTX
Foghorn Therapeutics
4.28
0.20
4.90%
VOR
Vor Biopharma
14.97
10.97
274.25%
AC Immune SA Corporate Events
AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO Retires
May 15, 2026
AC Immune has convened its 2026 Annual General Meeting for June 11, 2026, publishing the invitation and proxy materials and asking shareholders to vote on 2025 financial statements, compensation resolutions, director re-elections and amendments to...
AC Immune CEO and Co-Founder Andrea Pfeifer to Retire at June 11 AGM; Board Chair Martin Zügel Named Interim Chief
May 12, 2026
On May 12, 2026, AC Immune announced that co-founder and long-serving Chief Executive Officer Dr Andrea Pfeifer will retire from her role at the company’s Annual General Meeting on June 11, 2026, after a 23-year tenure. The board emphasized ...
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
Apr 30, 2026
On April 30, 2026, AC Immune SA reported that it had dosed the first patients in Cohort AD4 of its ongoing Phase 1b/2 ABATE trial of ACI-24, an anti-amyloid beta active immunotherapy for prodromal Alzheimer’s disease and adults with Down syn...
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
Apr 30, 2026
On April 30, 2026, AC Immune reported first-quarter 2026 financial and corporate updates, highlighting a cash position of CHF 74.8 million as of March 31, 2026, providing runway into the fourth quarter of 2027 and reflecting reduced RD spending af...
AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront
Apr 7, 2026
On April 7, 2026, AC Immune SA announced it had amended its 2018 license and collaboration agreement with Eli Lilly to advance Tau aggregation inhibitor small molecules, including new lead Morphomer Tau candidates and backup compounds, for potenti...
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027
Mar 13, 2026
AC Immune reported its full-year 2025 results on March 13, 2026, highlighting positive interim Phase 2 data for its wholly owned active immunotherapy ACI-7104, which appeared to slow progression in early Parkinson’s disease and showed a favo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.